1. Home
  2. DFNS vs TPST Comparison

DFNS vs TPST Comparison

Compare DFNS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFNS

T3 Defense Inc. Common Stock

N/A

Current Price

$0.60

Market Cap

27.2M

ML Signal

N/A

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

30.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFNS
TPST
Founded
2013
2011
Country
United States
United States
Employees
15
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
30.9M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
DFNS
TPST
Price
$0.60
$1.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.2M
128.8K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.60
52 Week High
$2.68
$12.22

Technical Indicators

Market Signals
Indicator
DFNS
TPST
Relative Strength Index (RSI) 19.61 29.65
Support Level N/A N/A
Resistance Level $2.44 $2.49
Average True Range (ATR) 0.12 0.16
MACD -0.02 -0.03
Stochastic Oscillator 17.99 12.50

Price Performance

Historical Comparison
DFNS
TPST

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: